Press Releases Archive

Pressemitteilungen Archiv 2017

Lophius augments its round of financing

(No. 185) The company located in BioPark Regensburg announced the augmentation of the first tranche of  the just recently completed round of financing from 5.2 million € to 7.4 million €. Participating in the augmentation of financing are VRD GmbH, one of the current key investors, "Growth Fund for Bavaria" from Bayern Kapital GmbH and Wolf Biotech GmbH.

Successful Start by Assay.Works in Regensburg

(Nr. 184) At BioPark Regensburg a new service provider for potential new drug therapies has gone into operation by the name Firma Assay.Works GmbH. Here the Regensburg enterprise is working closely together with the company Metrion Biosciences Ltd in Cambridge, UK.

Sixth Workshop on Health Care Sector

(No. 183) „Innovation & Startup Founding“ was discussed as the focus topic during the sixth workshop of the event series for developing a „Health Care Sector Masterplan“ for the region of Regensburg. At the BioPark, stakeholders from both academia and research institutions, as well as from start-up advisory services and economic development, together with experienced company founders have jointly collected content input for this key topic of the masterplan. The finalized masterplan is planned to be released in fall 2017.

Current BioPark Annual Report 2016

(No. 182) The current development of the life science companies in BioRegion Regensburg demonstrates a stable number of companies and employees in East Bavaria. The new business figures presented by BioPark Regensburg GmbH for 2016 are for the Cluster in East Bavaria with 50 companies and 3,872 employees.

Fifth Workshop on Health Care Sector

(No. 181) In the fifth workshop of the event series for developing a „Health Care Sector Masterplan“ for the region of Regensburg, the content cornerstones for the topics „Location Marketing & Economic Development“ have now been set. In the beginning of 2017 another workshop with the topic of “Innovation & Company Founding” will follow.